Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Antibe Therapeutics Inc(Pre-Merger) ATBPF

Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug, otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.


GREY:ATBPF - Post by User

Post by AwareInvestoron Feb 11, 2021 4:49pm
174 Views
Post# 32544292

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.

Antibe Therapeutics: Canaccord Upgrades Price Target To $16.
Earlier this week, Antibe Therapeutics announced a strategic licensing deal with Nuance Pharm in China. The deal includes a U$20 million upfront payment, with U$100 million in milestone payments from Nuance Pharma. The agreement provides Nuance with exclusive rights to commercialize otenaproxesul, Antibe’s chronic pain drug, in China, Hong Kong, Macau, and Taiwan.
 
Antibe Therapeutics currently has six analysts covering the company with a weighted 12-month price target of C$15.68. This is down from the average last month, which was C$18.22. One analyst has a strong buy rating while the other five have buy ratings.

https://thedeepdive.ca/antibe-therapeutics-canaccord-upgrades-price-target-to-16-50/
<< Previous
Bullboard Posts
Next >>